BCL2L11 and non-small cell lung carcinoma: The combination of aspirin and osimertinib inhibited AKT/FOXO3a signaling component phosphorylation and increased Bim expression in osimertinib-resistant NSCLC cells and promoted Bim-dependent apoptosis, which decreased tumor growth in vivo (Han et al., 2020).